Clinical Trial

Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical trial aims to explore and evaluate the efficacy and safety of combined chemotherapy with arsenic trioxide for stage 4/M neuroblastoma.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-04-11; most recent amendment 2025-05-19.
Status change: Recruiting → Active, Not Recruiting 2025-05-19
Trial Details
NCT Number NCT03503864
Lead Sponsor Yang Li
Conditions Neuroblastoma
Enrollment 80 participants
Start Date 2017-06-12
Primary Completion 2023-08-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-21